Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald Thornton

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2006
Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitorLisa J Green, Philip Marder, Chad Ray, et al.
Anti-Cancer Drugs|November 29, 2007
A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumorsD Ross Camidge, S Gail Eckhardt, Lia Gore, et al.
Cancer Research|August 17, 2005
The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenograftsJeremy R Graff, Ann M McNulty, Kimberly Ross Hanna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2007
Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphomaMichael J Robertson, Brad S Kahl, Julie M Vose, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2006
Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitorLisa J Green, Philip Marder, Chad Ray, et al.
Anti-Cancer Drugs|November 29, 2007
A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumorsD Ross Camidge, S Gail Eckhardt, Lia Gore, et al.
Cancer Research|August 17, 2005
The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenograftsJeremy R Graff, Ann M McNulty, Kimberly Ross Hanna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2007
Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphomaMichael J Robertson, Brad S Kahl, Julie M Vose, et al.
Pageof 2